ClinicalTrials.gg
TerminatedNCT03682497Updated May 1, 2020

Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium

A Phase 1 interventional study of AZD9977 and Spironolactone in Heart Failure, sponsored by AstraZeneca. Terminated at 18 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-05-01.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Why this study was terminated
Attendance at study sites carries risk of COVID-19 infection. Non-attendance at planned study site visits has unacceptable study related patient safety risk.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Heart Failure by AstraZeneca — 6 open to participants now, 8 under way, 3 of them phase 3. Heart Failure · AstraZeneca.

Enrollment
25th of 39
68 · median 160
Started
2018
with 7 others
Phase 1
13 of 64
none open now
Registered
24th of 64
by date

Among the 64 studies in Heart Failure by AstraZeneca, this one is the 25th largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2018, is one of 13 in phase 1, and was the 24th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 64 studies in Heart Failure by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Heart Failure by AstraZeneca, or all of them as a file.
02

Study summary

This is a Phase I, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium [sK+] during 28 days in Patients with HFmrEF or HFpEF and eGFR in the range of ≥40 and ≤70 mL/min/1.73m2.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart failure.
  • Oral selective mineralocorticoid receptor modulator.
  • Heart failure with preserved ejection fraction (HFpEF).
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptoms and signs consistent with a diagnosis of heart failure (HF)
  • (LVEF) ≥40% by transthoracic echocardiography within the past 12 months
  • Plasma NT-proBNP level ≥125 pg/ml (≥ 600pg/mL if patient has persistent or permanent atrial fibrillation, atrial flutter, or atrial tachycardia)
  • Estimated (eGFR) ≥40 and ≤70ml/min/1.73m2 (by CKD-EPI formula).
  • Baseline serum potassium (sK+) level ≥3.5 and ≤4.8mmol/l.
  • Stable doses of the following medications at baseline for at least 4 weeks prior to randomisation:

Angiotensin receptor blocker (ARB) or Angiotensin converting enzyme inhibitor (ACEi) Loop diuretic (up to a 120mg furosemide dose or equivalent

Exclusion criteria

Exclusion Criteria:

  • Patients with documented \<40% at any time (i.e. patients with previously impaired LVEF that has now improved are not permitted).
  • Patients experiencing acute decompensation of heart failure requiring hospital admission or escalation in therapy.
  • Primary cardiomyopathy (e.g. constrictive, restrictive, infiltrative, toxic, hypertrophic, congenital or any primary cardiomyopathy in judgment of Investigator).
  • Hyponatraemia, defined as serum Na+ \<135 mmol/L at the time of enrollment.
  • Persistent resting sinus tachycardia >110 bpm or sinus bradycardia \<45bpm.
  • Systolic blood pressure (BP) \<110mmHg or >180mmHg.
  • Diastolic BP \<60 mmHg or >100 mmHg.
  • Patients previously intolerant to MRA (e.g. spironolactone or eplerenone) for any reason.
  • Medical conditions associated with development of hyperkalaemia (e.g. Addison's disease).
  • (ALT) or aspartate aminotransferase (AST) level ≥2.0 times the (ULN).
  • Patients who have been taking an MR antagonist within 1 month prior to randomization.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Active comparator
    Spironolactone

    Spironolactone treatment for 28 days

    Drug: Spironolactone

  • Experimental
    AZD9977

    AZD9977 treatment for 28 days

    Drug: AZD9977

Interventions

  • AZD9977 capsules taken orally for 28 days.

  • Spironolactone tablets taken orally for 28 days.

06

What researchers measure

Primary outcomes

  1. Relative change (%) from baseline in serum potassium

    To compare the effect of AZD9977 with spironolactone on serum potassium (sK+)

    Time frame: Measurements on day 1, 7, 14, 21 and 28 will be used. The primary comparison between Spironolactone and AZD9977 will be done at day 28.

Secondary outcomes

  1. Plasma trough concentrations (Ctrough) values of spironolactone and AZD9977

    To evaluate the pharmacokinetics (PK) of AZD9977 and spironolactone

    Time frame: PK samples will be taken (within 60 min prior to dose) at day 1, 7, 14, 21 and 28.

  2. Relative change (%) from baseline in serum potassium

    To compare the effects of AZD9977 with spironolactone on serum potassium at Day 14.

    Time frame: Measurements on day 1, 7 and 14 will be used. The primary comparison between Spironolactone and AZD9977 will be done at day 14.

07

Study locations

18 sites
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Sofia, 1309, Bulgaria
  • Research Site
    Sofia, 1784, Bulgaria
  • Research Site
    Brandys nad Labem, 250 01, Czechia
  • Research Site
    Ceska Lipa, 470 77, Czechia
  • Research Site
    Jaromer, 551 01, Czechia
  • Research Site
    Louny, 440 01, Czechia
  • Research Site
    Pardubice, 530 02, Czechia
  • Research Site
    Praha, 130 00, Czechia
  • Research Site
    Praha, 140 59, Czechia
  • Research Site
    Katowice, 40-081, Poland
  • Research Site
    Kraków, 31-202, Poland
  • Research Site
    Legnica, 59-220, Poland
  • Research Site
    Warszawa, 02-097, Poland
  • Research Site
    Wrocław, 50-981, Poland
  • Research Site
    Hull, HU3 2JZ, United Kingdom
  • Research Site
    Leicester, LE3 9PQ, United Kingdom
  • Research Site
    Sheffield, S5 7AU, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Mar 2020, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2018
First posted
Sep 24, 2018
StartActual
Nov 1, 2018
Primary completionActual
Mar 31, 2020
CompletionActual
Mar 31, 2020
Last update
May 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03682497
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 24, 2018
Start date
Nov 1, 2018
Primary completion
Mar 31, 2020
Completion
Mar 31, 2020
Last update
May 1, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9977

Start the discussion